'''Anipamil''' is a [[calcium channel blocker]],<ref>{{Cite journal|last=Raddino|first=Riccardo|last2=Poli|first2=Enzo|last3=Pasini|first3=Evasio|last4=Ferrari|first4=Roberto|date=1992-09-01|title=Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart|url=https://link.springer.com/article/10.1007/BF00173549|journal=Naunyn-Schmiedeberg's Archives of Pharmacology|language=en|volume=346|issue=3|pages=339–344|doi=10.1007/BF00173549|issn=0028-1298}}</ref> specifically of the [[phenylalkylamine]] type. This type is separate from its more common cousin [[Dihydropyridine]]. Anipamil is an analog of the more common drug [[verapamil]], which is the most common type of [[phenylalkylamine]] style calcium channel blocker. Anipamil has been shown to be a more effective antiarrhythmic medication<ref name=":0">{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/002432059502070Y|title=Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia |language=en|access-date=2017-05-11|doi=10.1016/0024-3205(95)02070-Y|volume=57|issue=12|journal=Life Sciences|pages=1219–1231 | last1 = Pugsley | first1 = M.K.}}</ref> than [[verapamil]] because it does not cause hypertension as seen in [[verapamil]].<ref>{{Cite journal|last=Lefrandt|first=J. D.|last2=Heitmann|first2=J.|last3=Sevre|first3=K.|last4=Castellano|first4=M.|last5=Hausberg|first5=M.|last6=Fallon|first6=M.|last7=Fluckiger|first7=L.|last8=Urbigkeit|first8=A.|last9=Rostrup|first9=M.|date=2001-11-01|title=The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study|url=https://www.ncbi.nlm.nih.gov/pubmed/11724204|journal=American Journal of Hypertension|volume=14|issue=11 Pt 1|pages=1083–1089|issn=0895-7061|pmid=11724204}}</ref> It is able to do this by bonding to the [[myocardium]] tighter then [[verapamil]].<ref name=":0" />
